Summary
Vertex Pharmaceuticals (VRTX) has filed an 8-K report detailing significant events impacting its financial statements and operations as of December 31, 2013. The company is deconsolidating Alios's financial statements, a move classified as a disposition of assets with no exchange of consideration. This action is a direct consequence of Vertex recognizing a full impairment of its intangible asset related to the VX-135 (HCV nucleotide analogue) program. Investors should note the substantial $250.6 million impairment charge recorded in the fourth quarter of 2013 for VX-135. This impairment was driven by adverse safety, tolerability, efficacy data, an ongoing FDA partial clinical hold, and a competitive review of the hepatitis C market. While this charge is significant, Vertex states it will not result in future cash expenditures. The deconsolidation of Alios is intrinsically linked to this impairment and will be reflected in pro-forma financial statements to be filed shortly.
Key Highlights
- 1Vertex Pharmaceuticals has deconsolidated Alios's financial statements effective December 31, 2013, treating it as a disposition of assets.
- 2No consideration was exchanged in the deconsolidation of Alios.
- 3A significant impairment charge of $250.6 million was recorded in Q4 2013 for the VX-135 (HCV nucleotide analogue) intangible asset.
- 4The impairment of VX-135 was due to negative clinical data, an FDA partial clinical hold, and a challenging competitive landscape for Hepatitis C treatments.
- 5The fair value of the VX-135 intangible asset was determined to be zero as of December 31, 2013.
- 6A $102.1 million tax benefit was recorded related to the impairment charge.
- 7The company expects no future cash expenditures resulting from this impairment charge.